Bertek Nebivolol NDA Submission Could Yield Third Branded Antihypertensive
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Mylan’s branded drugs subsidiary Bertek is closer to adding a third hypertension drug to its product lineup with the submission of an NDA for the cardioselective beta blocker nebivolol. The firm thinks the agent could serve as the cornerstone of its branded business.